The Telegraph reports that "intensive care for coronavirus patients now limited to those 'reasonably certain' to survive, NHS London Trust concedes".
A department head at Imperial College Healthcare revealed on Sunday that fewer and fewer marginal patients are being selected for ventilator treatment because so many serious cases require a fortnight on the machines.
It comes as the NHS faces the toughest week in its history, with the Deputy Chief Medical Officer, Dr Jenny Harries, warning the number of deaths will increase.
Imperial College Healthcare acknowledged that “very poorly patients with coronavirus may need to be on a ventilator for extended periods," adding that "for some patients this would not be in their best interests”, but denied people are being denied care due to capacity problems....
That is tragic news and will weigh on UK sentiment hugely, although it was likely already a concern and proceed into the market.
GBP/USD: Above 21-day SMA amid bullish MACD: GBP/USD registers five-day winning streak, probes 50% Fibonacci retracement. A clear break of 21-day SMA, bullish MACD favor buyers. 200-day SMA, 61.8% Fibonacci retracement on the bulls’ radars.
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers. The author will not be held responsible for information that is found at the end of links posted on this page.
If not otherwise explicitly mentioned in the body of the article, at the time of writing, the author has no position in any stock mentioned in this article and no business relationship with any company mentioned. The author has not received compensation for writing this article, other than from FXStreet.
FXStreet and the author do not provide personalized recommendations. The author makes no representations as to the accuracy, completeness, or suitability of this information. FXStreet and the author will not be liable for any errors, omissions or any losses, injuries or damages arising from this information and its display or use. Errors and omissions excepted.
The author and FXStreet are not registered investment advisors and nothing in this article is intended to be investment advice.